N-hexacosanol prevents diabetes-induced rat ileal dysfunction without qualitative alteration of the muscarinic receptor system
Related Experiment Video
Updated: Jul 10, 2026

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes
Published on: September 9, 2021
Naho Narimatsu1, Motoaki Saito, Emi Kazuyama
1Department of Pathophysiological and Therapeutic Science, Division of Molecular Pharmacology, Tottori University Faculty of Medicine, Nishimachi, Yonago.
Abstract:
We evaluated the effects of N-hexacosanol, a cyclohexenonic long-chain fatty alcohol, on muscarinic receptors in diabetic rat ileal dysfunction. Eight-week-old male SD rats were divided into four groups. After induction of diabetes (streptozotocin 50 mg/kg, i.p.), three groups were maintained for eight weeks with treatment by N-hexacosanol (0, 2 or 8 mg/kg, s.c. every day). Ileum function was investigated by organ bath studies using carbachol and KCl, and the expression levels of muscarinic M(2) and M(3) receptors were investigated by real-time polymerase chain reaction. Various concentrations of subtype-selective muscarinic antagonists, i.e., atropine (non-selective), pirenzepine (M(1) selective), methoctramine (M(2) selective), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP, M(1)/M(3) selective), were used in this study. In the presence and absence of these antagonists, contractile response curves to increasing concentrations of carbachol were investigated. Treatment with N-hexacosanol did not alter the diabetic status of the rats, but did significantly prevent the carbachol-induced hypercontractility in diabetic rat ileum. Estimation of the pA(2) values for atropine, pirenzepine, methoctramine, and 4-DAMP indicated that the carbacholinduced contractile response in the ileum is mainly mediated through the muscarinic M(3) receptor subtype in all groups. Furthermore, N-hexacosanol significantly prevented the diabetes-induced up-regulation of intestinal muscarinic M(2) and M(3) receptor mRNAs in streptozotocin-diabetic rats. Our data indicated that N-hexacosanol exerts preventive effects with respect to carbachol-induced hypercontractility in the diabetic rat ileum without qualitative alteration of the muscarinic receptor system.
Insights
N-hexacosanol prevents carbachol-induced hypercontractility in diabetic rat ileum by targeting muscarinic M(3) receptors. This long-chain fatty alcohol also reduces diabetes-induced up-regulation of muscarinic M(2) and M(3) receptor mRNAs.
Area of Science:
- Pharmacology
- Gastroenterology
- Endocrinology
Background:
- Diabetic gastrointestinal dysfunction is a common complication.
- Muscarinic receptors play a role in regulating intestinal motility.
- Alterations in muscarinic receptor expression are observed in diabetic states.
Purpose of the Study:
- To investigate the effects of N-hexacosanol on muscarinic receptor function in diabetic rat ileum.
- To determine if N-hexacosanol can ameliorate carbachol-induced hypercontractility in diabetic ileum.
- To examine the impact of N-hexacosanol on muscarinic M(2) and M(3) receptor expression in diabetic rats.
Main Methods:
- Diabetes was induced in Sprague-Dawley rats using streptozotocin.
- Rats were treated with varying doses of N-hexacosanol.
- Ileum function was assessed using organ bath studies with carbachol and KCl.
- Muscarinic receptor expression (M(2) and M(3)) was quantified using real-time PCR.
- Subtype-selective muscarinic antagonists were employed to characterize receptor involvement.
Main Results:
- N-hexacosanol treatment did not affect the overall diabetic status of the rats.
- N-hexacosanol significantly prevented carbachol-induced hypercontractility in the diabetic rat ileum.
- Carbachol-induced contractile responses were primarily mediated by the muscarinic M(3) receptor subtype.
- N-hexacosanol significantly attenuated the diabetes-induced upregulation of muscarinic M(2) and M(3) receptor mRNAs.
Conclusions:
- N-hexacosanol demonstrates preventive effects against carbachol-induced hypercontractility in the diabetic rat ileum.
- The protective action of N-hexacosanol is associated with the modulation of muscarinic M(3) receptor activity.
- N-hexacosanol mitigates diabetes-induced changes in intestinal muscarinic M(2) and M(3) receptor mRNA expression.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Dipeptidyl Peptidase 4 Inhibitors
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
